Rexahn Pharmaceuticals, Inc. (RNN) Submits Phase II Protocol to FDA for Clinical Study of Archexin as Treatment for Ovarian Cancer
Yesterday, clinical stage pharmaceutical company Rexahn Pharmaceuticals, Inc. announced it has submitted a phase II protocol to the U.S. Food…